Virbagest 4 mg/ml Oral Solution for Pigs

Država: Velika Britanija

Jezik: engleski

Izvor: VMD (Veterinary Medicines Directorate)

Aktivni sastojci:

Altrenogest

Dostupno od:

Virbac

ATC koda:

QG03DX90

INN (International ime):

Altrenogest

Farmaceutski oblik:

Oral solution

Tip recepta:

POM-V - Prescription Only Medicine – Veterinarian

Terapijska grupa:

Pigs

Područje terapije:

Hormone sex

Status autorizacije:

Authorized

Datum autorizacije:

2008-03-28

Svojstava lijeka

Revised: January 2017
AN: 01027/2016
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
VIRBAGEST 4 mg/ml oral solution for pigs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
Altrenogest
4.00 mg/ml
EXCIPIENTS:
Butylhydroxytoluene (E321)
0.07 mg/ml
Butylhydroxyanisole (E320)
0.07 mg/ml
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Oral solution.
For top-dressing use.
A clear colourless to pale yellow solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Pigs (nulliparous mature sows).
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the synchronisation of oestrus in nulliparous mature sows.
4.3
CONTRAINDICATIONS
Do not use in boars.
Do not administer to pregnant sows (see section 4.7) or those
suffering from uterine
infection.
Do not use in case of hypersensitivity to the active substance.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Revised: January 2017
AN: 01027/2016
Page 2 of 5
Ensure the correct dose is administered daily as under dosing can lead
to the
formation of cystic follicles.
Add the veterinary medicinal product to the feed immediately before
feeding. Discard
any uneaten medicated feed.
Use only in sexually mature gilts that have been in oestrus.
Part consumed feed must be safely disposed of and not given to any
other animal.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY
MEDICINAL PRODUCT TO ANIMALS
Women who are pregnant, or suspected to be pregnant, should not use
the product.
Women of childbearing age should handle the product with extreme care.
The
product should not be handled by persons with known or suspected
progesterone-
dependent tumours or thrombo-embolic disorders.
Direct contact with the skin should be avoided. Personal protective
clothing (gloves
and overalls) must be worn when handling the product. Porous gloves
may let this
product pass through. Transcutaneous absorption may be even higher
whe